{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T10:32:11Z","timestamp":1782642731729,"version":"3.54.5"},"reference-count":67,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2022R1A2C1010771"],"award-info":[{"award-number":["2022R1A2C1010771"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["RS-2024-00446415"],"award-info":[{"award-number":["RS-2024-00446415"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.molpha.2025.100062","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:47:02Z","timestamp":1752713222000},"page":"100062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Design and evaluation of highly selective histone deacetylase 6 inhibitors derived from the natural product tryptoline"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9942-4756","authenticated-orcid":false,"given":"Khan Hashim","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5515-2197","authenticated-orcid":false,"given":"Chiranjeev","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3125-2836","authenticated-orcid":false,"given":"Yong Jin","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6345-8035","authenticated-orcid":false,"given":"Ji Hoon","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6765-3693","authenticated-orcid":false,"given":"Soong-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ho","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.molpha.2025.100062_bib1","article-title":"Design, synthesis and biological evaluation of a series of CNS penetrant HDAC inhibitors structurally derived from amyloid-\u03b2 probes","volume":"9","author":"Choi","year":"2019","journal-title":"Sci Rep"},{"issue":"24","key":"10.1016\/j.molpha.2025.100062_bib2","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.3390\/ijms20246213","article-title":"Development of thiazolidinedione-based HDAC6 inhibitors to overcome methamphetamine addiction","volume":"20","author":"Sharma","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.molpha.2025.100062_bib3","doi-asserted-by":"crossref","first-page":"7900","DOI":"10.1021\/acs.jmedchem.0c02055","article-title":"Targeting epigenetic regulators with covalent small-molecule inhibitors","volume":"64","author":"Zhang","year":"2021","journal-title":"J Med Chem"},{"issue":"15","key":"10.1016\/j.molpha.2025.100062_bib4","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2174\/0929867325666181016163110","article-title":"Recent progress in histone deacetylase inhibitors as anticancer agents","volume":"27","author":"Cappellacci","year":"2020","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.molpha.2025.100062_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116057","article-title":"Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue","volume":"265","author":"Jha","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"7","key":"10.1016\/j.molpha.2025.100062_bib6","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40265-024-02052-1","article-title":"Givinostat: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.molpha.2025.100062_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400194","article-title":"Heterocycles\u2013containing HDAC inhibitors active in cancer: an overview of the last fifteen years","volume":"19","author":"Raucci","year":"2024","journal-title":"ChemMedChem"},{"issue":"21","key":"10.1016\/j.molpha.2025.100062_bib8","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.3390\/cancers14215251","article-title":"HDACi: The Columbus' egg in improving cancer treatment and reducing neurotoxicity?","volume":"14","author":"Squarzoni","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.molpha.2025.100062_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14366","article-title":"Discussion on structure classification and regulation function of histone deacetylase and their inhibitor","volume":"103","author":"Han","year":"2024","journal-title":"Chem Biol Drug Des"},{"issue":"9-10","key":"10.1016\/j.molpha.2025.100062_bib10","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s12272-023-01467-w","article-title":"Exploring new histone deacetylase 6 inhibitors and their effects on reversing the \u03b1-tubulin deacetylation and cell morphology changes caused by methamphetamine","volume":"46","author":"Gupta","year":"2023","journal-title":"Arch Pharm Res"},{"issue":"17","key":"10.1016\/j.molpha.2025.100062_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029049","article-title":"Design, synthesis, and biological evaluation of histone deacetylase inhibitor with novel salicylamide zinc binding group","volume":"101","author":"Kim","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.molpha.2025.100062_bib12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/13543776.2017.1276565","article-title":"Selective histone deacetylase small molecule inhibitors: recent progress and perspectives","volume":"27","author":"Qin","year":"2017","journal-title":"Expert Opin Ther Pat"},{"issue":"8","key":"10.1016\/j.molpha.2025.100062_bib13","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1007\/s00277-024-05691-2","article-title":"A real-world pharmacovigilance study investigating the toxicities of histone deacetylase inhibitors","volume":"103","author":"Li","year":"2024","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.molpha.2025.100062_bib14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","article-title":"Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.molpha.2025.100062_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/srep12917","article-title":"Deacetylation of \u03b1-tubulin and cortactin is required for HDAC6 to trigger ciliary disassembly","volume":"5","author":"Ran","year":"2015","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.molpha.2025.100062_bib16","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1124\/mol.110.065169","article-title":"The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity","volume":"78","author":"Chia","year":"2010","journal-title":"Mol Pharmacol"},{"issue":"8","key":"10.1016\/j.molpha.2025.100062_bib17","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s00221-024-06858-z","article-title":"HDAC6 modulates the cognitive behavioral function and hippocampal tissue pathological changes of APP\/PS1 transgenic mice through HSP90-HSF1 pathway","volume":"242","author":"Wang","year":"2024","journal-title":"Exp Brain Res"},{"key":"10.1016\/j.molpha.2025.100062_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114582","article-title":"Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay","volume":"240","author":"Chae","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"3","key":"10.1016\/j.molpha.2025.100062_bib19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/mol.116.103416","article-title":"Hybrid enzalutamide derivatives with histone deacetylase inhibitor activity decrease heat shock protein 90 and androgen receptor levels and inhibit viability in enzalutamide-resistant C4-2 prostate cancer cells","volume":"90","author":"Rosati","year":"2016","journal-title":"Mol Pharmacol"},{"issue":"8","key":"10.1016\/j.molpha.2025.100062_bib20","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1021\/acschembio.1c00303","article-title":"HDAC6 substrate discovery using proteomics-based substrate trapping: HDAC6 deacetylates PRMT5 to influence methyltransferase activity","volume":"16","author":"Gomes","year":"2021","journal-title":"ACS Chem Biol"},{"issue":"3","key":"10.1016\/j.molpha.2025.100062_bib21","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1021\/acs.jmedchem.1c01863","article-title":"Discovery of novel histone deacetylase 6 (HDAC6) inhibitors with enhanced antitumor immunity of anti-PD-L1 immunotherapy in melanoma","volume":"65","author":"Peng","year":"2022","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.molpha.2025.100062_bib22","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.molonc.2015.04.002","article-title":"Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation","volume":"9","author":"Woan","year":"2015","journal-title":"Mol Oncol"},{"key":"10.1016\/j.molpha.2025.100062_bib23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.molimm.2023.11.007","article-title":"Role of HDAC6-STAT3 in immunomodulatory pathways in colorectal cancer cells","volume":"164","author":"Mardones","year":"2023","journal-title":"Mol Immunol"},{"key":"10.1016\/j.molpha.2025.100062_bib24","article-title":"The role of HDAC6 in cancer","volume":"2011","author":"Aldana-Masangkay","year":"2011","journal-title":"J Biomed Biotechnol"},{"issue":"3","key":"10.1016\/j.molpha.2025.100062_bib25","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41388-020-01550-2","article-title":"HDAC6 promotes growth, migration\/invasion, and self-renewal of rhabdomyosarcoma","volume":"40","author":"Pham","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.molpha.2025.100062_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.123219","article-title":"Curriculum vitae of HDAC6 in solid tumors","volume":"230","author":"Zheng","year":"2023","journal-title":"Int J Biol Macromol"},{"issue":"46","key":"10.1016\/j.molpha.2025.100062_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adp3687","article-title":"The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy","volume":"10","author":"Kovalovsky","year":"2024","journal-title":"Sci Adv"},{"issue":"6","key":"10.1016\/j.molpha.2025.100062_bib28","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1158\/2767-9764.CRC-23-0528","article-title":"HDAC6 inhibition releases HR23B to activate proteasomes, expand the tumor immunopeptidome and amplify T-cell antimyeloma activity","volume":"4","author":"Rana","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"5","key":"10.1016\/j.molpha.2025.100062_bib29","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1021\/acs.jmedchem.4c02510","article-title":"Discovery of novel and highly potent dual PD-L1\/histone deacetylase 6 inhibitors with favorable pharmacokinetics for cancer immunotherapy","volume":"68","author":"Hu","year":"2025","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.molpha.2025.100062_bib30","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.molpha.2025.100062_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117218","article-title":"Small molecules targeting HDAC6 for cancer treatment: current progress and novel strategies","volume":"178","author":"Huang","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"13","key":"10.1016\/j.molpha.2025.100062_bib32","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-16-2526","article-title":"Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma","volume":"23","author":"Vogl","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.molpha.2025.100062_bib33","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1158\/1078-0432.CCR-21-0238","article-title":"Preclinical development and first-in-human study of KA2507, a selective and potent inhibitor of histone deacetylase 6, for patients with refractory solid tumors","volume":"27","author":"Tsimberidou","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.molpha.2025.100062_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.696512","article-title":"Selective histone deacetylase inhibitor ACY-241 (citarinostat) plus nivolumab in advanced non-small cell lung cancer: results from a phase Ib study. Clinical Trial","volume":"11","author":"Awad","year":"2021","journal-title":"Front Oncol"},{"issue":"13_Supplement","key":"10.1016\/j.molpha.2025.100062_bib35","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1158\/1538-7445.AM2021-645","article-title":"Abstract 645: Network-based assessment of HDAC6 activity is highly predictive of pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat","volume":"81","author":"Pan","year":"2021","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.molpha.2025.100062_bib36","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","article-title":"Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial","volume":"17","author":"Yee","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.molpha.2025.100062_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s43018-022-00489-5","article-title":"Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer","volume":"4","author":"Zeleke","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.molpha.2025.100062_bib38","article-title":"Phase Ib study of the histone deacetylase 6 inhibitor citarinostat in combination with paclitaxel in patients with advanced solid tumors","volume":"11","author":"Gordon","year":"2021","journal-title":"Front Oncol"},{"issue":"31","key":"10.1016\/j.molpha.2025.100062_bib39","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1021\/ja102758v","article-title":"Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A","volume":"132","author":"Butler","year":"2010","journal-title":"J Am Chem Soc"},{"issue":"14","key":"10.1016\/j.molpha.2025.100062_bib40","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1021\/jm100410f","article-title":"Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria","volume":"53","author":"Yeung","year":"2010","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.molpha.2025.100062_bib41","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1016\/j.bmcl.2008.04.030","article-title":"Synthesis of 2-[3-(7-Chloro-quinolin-4-ylamino)-alkyl]-1-(substituted phenyl)-2,3,4,9-tetrahydro-1H-beta-carbolines as a new class of antimalarial agents","volume":"18","author":"Gupta","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"issue":"17","key":"10.1016\/j.molpha.2025.100062_bib42","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1016\/j.bmcl.2006.06.024","article-title":"Dual-acting agents that possess free radical scavenging and antithrombotic activities: design, synthesis, and evaluation of phenolic tetrahydro-beta-carboline RGD peptide conjugates","volume":"16","author":"Bi","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"issue":"22","key":"10.1016\/j.molpha.2025.100062_bib43","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.1016\/j.bmc.2007.08.022","article-title":"Design, synthesis and cardioprotective effect of a new class of dual-acting agents: phenolic tetrahydro-beta-carboline RGD peptidomimetic conjugates","volume":"15","author":"Bi","year":"2007","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"10.1016\/j.molpha.2025.100062_bib44","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bmcl.2009.10.123","article-title":"Substituted tetrahydro-beta-carbolines as potential agents for the treatment of human papillomavirus infection","volume":"20","author":"Miller","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"10.1016\/j.molpha.2025.100062_bib45","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.ejmech.2010.02.001","article-title":"Synthesis and cytotoxicity evaluation of (tetrahydro-beta-carboline)-1,3,5-triazine hybrids as anticancer agents","volume":"45","author":"Kumar","year":"2010","journal-title":"Eur J Med Chem"},{"issue":"16","key":"10.1016\/j.molpha.2025.100062_bib46","doi-asserted-by":"crossref","first-page":"7728","DOI":"10.1016\/j.bmc.2008.07.002","article-title":"Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4","volume":"16","author":"Jenkins","year":"2008","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"10.1016\/j.molpha.2025.100062_bib47","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.phytol.2010.07.010","article-title":"Callophycin A, a cytotoxic tetrahydro-\u03b2-carboline from the red alga Callophycus oppositifolius","volume":"4","author":"Ovenden","year":"2011","journal-title":"Phytochem Lett"},{"issue":"21","key":"10.1016\/j.molpha.2025.100062_bib48","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1016\/j.bmc.2011.09.020","article-title":"Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents","volume":"19","author":"Shen","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.molpha.2025.100062_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110454","article-title":"Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells","volume":"129","author":"Dawood","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"29","key":"10.1016\/j.molpha.2025.100062_bib50","doi-asserted-by":"crossref","first-page":"47890","DOI":"10.18632\/oncotarget.18141","article-title":"Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6","volume":"8","author":"Tan","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.molpha.2025.100062_bib51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4196\/kjpp.2024.28.1.83","article-title":"ACY-241, a histone deacetylase 6 inhibitor, suppresses the epithelial-mesenchymal transition in lung cancer cells by downregulating hypoxia-inducible factor-1 alpha","volume":"28","author":"Park","year":"2024","journal-title":"Korean J Physiol Pharmacol"},{"issue":"10","key":"10.1016\/j.molpha.2025.100062_bib52","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1016\/j.bmcl.2012.03.077","article-title":"Structure-activity relationship in the antitumor activity of 6-, 8- or 6,8-substituted 3-benzylamino-\u03b2-carboline derivatives","volume":"22","author":"Ikeda","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"issue":"14","key":"10.1016\/j.molpha.2025.100062_bib53","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1021\/acs.jmedchem.8b00393","article-title":"Discovery of janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors as a novel strategy for the combinational treatment of leukemia and invasive fungal infections","volume":"61","author":"Huang","year":"2018","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.molpha.2025.100062_bib54","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s13402-022-00704-6","article-title":"HDAC6: a unique HDAC family member as a cancer target","volume":"45","author":"Kaur","year":"2022","journal-title":"Cell Oncol"},{"key":"10.1016\/j.molpha.2025.100062_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105274","article-title":"HDAC6 as privileged target in drug discovery: a perspective","volume":"163","author":"Pulya","year":"2021","journal-title":"Pharmacol Res"},{"issue":"9","key":"10.1016\/j.molpha.2025.100062_bib56","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3390\/ph3092751","article-title":"Clinical toxicities of histone deacetylase inhibitors","volume":"3","author":"Subramanian","year":"2010","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.molpha.2025.100062_bib57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/epi.14.69","article-title":"Histone deacetylase 6 in health and disease","volume":"7","author":"Seidel","year":"2015","journal-title":"Epigenomics"},{"issue":"5","key":"10.1016\/j.molpha.2025.100062_bib58","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1128\/MCB.01154-06","article-title":"Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally","volume":"28","author":"Zhang","year":"2008","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.molpha.2025.100062_bib59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/B978-0-12-394387-3.00002-1","article-title":"Mechanisms of resistance to histone deacetylase inhibitors","volume":"116","author":"Lee","year":"2012","journal-title":"Adv Cancer Res"},{"issue":"6","key":"10.1016\/j.molpha.2025.100062_bib60","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.tcb.2008.04.003","article-title":"HDAC6: a key regulator of cytoskeleton, cell migration and cell\u2013cell interactions","volume":"18","author":"Valenzuela-Fern\u00e1ndez","year":"2008","journal-title":"Trends Cell Biol"},{"issue":"11","key":"10.1016\/j.molpha.2025.100062_bib61","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.molpha.2025.100062_bib62","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3892\/ol.2021.12462","article-title":"HDAC6-selective inhibitors enhance anticancer effects of paclitaxel in ovarian cancer cells","volume":"21","author":"Yoo","year":"2021","journal-title":"Oncol Lett"},{"key":"10.1016\/j.molpha.2025.100062_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116571","article-title":"Advances in dual-targeting inhibitors of HDAC6 for cancer treatment","volume":"275","author":"Gu","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.molpha.2025.100062_bib64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejmech.2016.12.039","article-title":"Ring-opened tetrahydro-\u03b3-carbolines display cytotoxicity and selectivity with histone deacetylase isoforms","volume":"127","author":"Nepali","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.molpha.2025.100062_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.molpha.2025.100062_bib66","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1038\/s41598-020-62678-5","article-title":"Inhibition of HDAC6 activity protects dopaminergic neurons from alpha-synuclein toxicity","volume":"10","author":"Francelle","year":"2020","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.molpha.2025.100062_bib67","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.4103\/NRR.NRR-D-23-01633","article-title":"Enhanced autophagic clearance of amyloid-\u03b2 via histone deacetylase 6-mediated V-ATPase assembly and lysosomal acidification protects against Alzheimer's disease in vitro and in vivo","volume":"20","author":"Long","year":"2025","journal-title":"Neural Regen Res"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X25153224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X25153224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:55:02Z","timestamp":1772794502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X25153224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0026895X25153224"],"URL":"https:\/\/doi.org\/10.1016\/j.molpha.2025.100062","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and evaluation of highly selective histone deacetylase 6 inhibitors derived from the natural product tryptoline","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molpha.2025.100062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100062"}}